Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma

Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma

BackgroundPembrolizumab, a PD-1 immune checkpoint inhibitor, is approved as first-line (1L) treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) as monotherapy or in combination with platinum and 5-fluorouracil chemotherapy. Limited data exist on the use of these r...

Full description

Bibliographic Details
Main Authors: Christopher M. Black, Glenn J. Hanna, Liya Wang, Karthik Ramakrishnan, Daisuke Goto, Vladimir Turzhitsky, Gleicy M. Hair
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Oncology
Subjects:
head and neck squamous cell carcinoma
antineoplastic agents
immunological
antibodies
Kaplan-Meier estimate
patient outcomes
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1160144/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1160144/full

Similar Items